TheraCryf PLC
TCF
Company Profile
Business description
TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.
Contact
Congleton Road
Alderley Park
Nether AlderleyCheshireSK10 4TG
GBRT: +44 1625315090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
9
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,611.70 | 38.30 | 0.45% |
| CAC 40 | 7,914.51 | 27.91 | -0.35% |
| DAX 40 | 24,038.31 | 2.20 | 0.01% |
| Dow JONES (US) | 42,677.24 | 114.83 | -0.27% |
| FTSE 100 | 8,785.63 | 4.51 | 0.05% |
| HKSE | 23,791.29 | 109.81 | 0.46% |
| NASDAQ | 19,142.71 | 72.75 | -0.38% |
| Nikkei 225 | 37,298.98 | 230.51 | -0.61% |
| NZX 50 Index | 12,703.10 | 58.87 | 0.47% |
| S&P 500 | 5,940.46 | 23.14 | -0.39% |
| S&P/ASX 200 | 8,386.80 | 43.50 | 0.52% |
| SSE Composite Index | 3,387.57 | 7.10 | 0.21% |